A healthy gain was recorded on Vinings Holdings Inc. (OTCPK-NDYN) stock as it gained 19.05% to $5.0000 at last close. Last week, Vinings stock scored 25.00% versus 57.48 percent for the month. Technology co-development agreements helped NDYN stock rise.
What agreements have been made by NDYN?
Vinings is a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical products in the branded and generic categories. Besides two approved drugs, NDYN has two drugs that are still in the clinical trials stage.
In addition, to be a holding company, NDYN is also the parent company of Coeptis Pharmaceuticals, Inc. NDYN offers Conjupri (levamlodipine) tablets to treat high blood pressure and Consensi (amlodipine and celecoxib) to treat osteoarthritis pain.
Earlier this month, Vinings announced that its subsidiary Coeptis Pharmaceuticals, Inc. entered into two separate exclusive option agreements with VyGen Bio.
- VyGen is the majority-owned subsidiary of Vycellix, Inc.
- The agreements covered the testing of technologies that may be used to treat cancers linked to CD38.
- There are two technologies of CD38-GEAR-NK and CD38-Diagnostic were involved in the agreement.
- CD38-GEAR-NK was created for the purpose of protecting CD38+ natural killer (NK) cells from destruction by monoclonal antibodies (mAbs) against CD38.
- CD38-Diagnostic, on the other hand, is an in vitro diagnostic tool being developed to determine whether a cancer patient is a candidate for anti-CD38 mAb therapy.
- Researchers at the Karolinska Institutet in Sweden discovered the Gene-Edited Antibody Resistant NK Platform (GEAR-NK), which VyGen-Bio is using to advance both the therapeutics.
Have any agreements been reached?
Specifically, Coeptis purchased the exclusive option to use the Vinings (NDYN)’s CD38-GEAR-NK technology from VyGen-Bio for a non-refundable fee. In regards to the second option, VyGen-Bio received a non-refundable fee from NDYN’s Coeptis for the exclusive option to sell the CD38-Diagnostic technology to Coeptis.
